臺灣博碩士論文加值系統

Oxacillin抗藥性金黃色葡萄球菌(oxacillin resistant Staphylococcus aureus; ORSA)是院內感染主要致病菌之一， 台灣近十年來社區oxacillin抗藥性金黃色葡萄球菌(community-onset Staphylococcus aureus ; CO-ORSA)盛行率明顯的增加，這些CO-ORSA不像醫院的ORSA感染者有明顯的指標因子。本研究為了解南部某醫學中心之CO-ORSA感染或移生的情形、可能危險因子和抗生素感受性表現，採病例對照研究，對象來自2003年1月至10月間，門、急診或住院未滿48小時之病患，其細菌培養為ORSA或OSSA者。共收集個案及對照組各158人, 進行統計分析。
結果發現：CO-ORSA最常發生感染或移生的部位，以皮膚軟組織(44.3%)為最常見、傷口(17.7%)次之、三為血流感染(15.2%)，和CO-OSSA組比較，無統計學上的差異(p>.05)。CO-ORSA者平均年齡52.9±18.6歲、有39.5%(62/157)需要使用輔助器(如柺杖或助行器)或長期臥床、平均同住人口數4.8±1.5人、有8.3%(13/157)住在長期照護機構、過去一年內平均門急診次數50.6±35.9人次、平均住院次數1.2±1.7人次,相較於CO-OSSA者，具有統計學上的差異（p＜.05）。門急診次數和住院次數愈多，呈現dose-response effect。與CO-OSSA組相比，CO-ORSA者有較多惡性血液腫瘤(24.1%)、腦血管病變(10.1%)、慢性鼻病(7.0%)等慢性病（p＜.05）;糖尿病、慢性腎衰竭、慢性皮膚病和呼吸道疾病，則無統計學上的差異(p>.05)。有較多的CO-ORSA者在過去三個月內曾接受抗生素、手術、導尿管、鼻胃管等治療（p＜.05）。以logistic regression分析比較，居住在長期照護機構、行動不便、腦血管病變、慢性鼻病、曾經住院與否和抗生素使用，是CO-ORSA感染或移生之獨立危險因子。大部分的CO-ORSA對抗生素的感受性普遍降低，包括co-trimoxazole(62%)、chloramphenicol(61%)、netilmicin(61%)、gentamicin(59%)、cefazolin(48%)、amoxicillin/clavulanate(48%)、ampicillin/sulbactam(47%)、clidamycin(21%)。25位皮膚軟組織或傷口感染CO-ORSA者，在治療的過程中仍可持續帶菌長達六個月之久。研究結果顯示：對於皮膚軟組織或傷口曾經感染ORSA，有行動不便、慢性鼻病、腦血管病變、最近一年內曾經住院或近三個月內曾經使用抗生素者，在個案再次入院時，醫院應儘早實施感染管制措施，以降低ORSA在醫院中交互感染的發生。

Oxacillin-resistant Staphylococcus aurues (ORSA) is one of the important nosocomial pathogens .The prevalence of community-onset ORSA (CO-ORSA) in Taiwan has increased markedly in the past 10 years. CO-ORSA patients had no significant predisposing factors which is different from the nosocomial ORSA. A retrospective case-control comparison study of the clinical characteristics, risk factors and antibiotics susceptibility for CO-ORSA compared with CO-OSSA (community-onset oxacillin-susceptible Staphylococcus aurue ) infection or colonization in adult outpatients was performed from January 2003 to October 2003 at Kaoshiung Medical University Hospital. One hundred and fifty eight CO-ORSA and 158 CO-OSSA infected patients were enrolled in this study for comparison and analysis. The results show that the most common site of CO-ORSA infection or colonization was skin and soft tissue (44.3%), following by wound (17.7%) and blood stream (15.2%). The percentage of patients infected with CO-OSSA was similar to the CO-ORSA. The average age of CO-ORSA group were 52.9± 18.6 years, and 39.5% (62/157) of them need walker or were bed-ridden. The average amount of people who living together were 4.8 ±1.5,and 8.3 % of them lived in LCTFs; The average times of visiting OPD and / or ER were 50.6 ±35.9. The frequencies of hospitalization were 1.2 ±1.7 , which had significant difference compared to CO-OSSA group. It shows a significant dose-effect response in the number of admissions or OPD/ER visit in group of CO-ORSA. In comparing with CO-OSSA patients , CO-ORSA patients had higher percentage of malignancy (24.1%), cerebral-vascular accidents (10.1%) and chronic nasal disease ( 7.0%).Use of antibiotics, surgery, foley catheters and nasal-gastric tube in the previous 3 months were commonly seen in patients with CO-ORSA infected which is statistically significant (p< .05). After Logistic regression analysis, the independent risk factors for developing CO-ORSA were residing in LCTF, disabilities, chronic nasal disease , cerebral-vascular accidents, use of antibiotics and previous hospitalization. Most of the isolated CO-ORSA had a low susceptibility against most antibiotics, including co-trimoxazole (62%), chloramphenicol (61%), netilmicin (61%) , gentamicin (59%), amoxicillin/clavulanate (48%), cefazolin (48%), ampicillin/sulbactam (47%) and clindamycin (21%). During the process of medical treatment, CO-ORSA can be carried for 6 months. According to the study, the patient of skin or soft tissue ORSA infection, precautions of infection control should be performed as early as possible to reduce the rate of cross- infection when they admitted again.

第一章 緖論
第一節 研究背景及動機...... ..........................................1
第二節 研究目的.......................................................6

第二章 文獻探討
第一節 金黃色葡萄球菌菌株介紹.........................................7
第二節 Oxacillin抗藥性金黃色葡萄球菌(ORSA)菌株介紹...................12
第三節 醫院及社區ORSA流行病學........................................14

第三章 材料與方法
第一節 研究假設..................................................... 22
第二節 研究流程..................................................... 23
第三節 研究架構......................................................24
第四節 研究對象................................................... 25
第五節 資料收集... .................................................. 27
第六節 統計分析..................................................... 33

第四章 結果
第一節 社區ORSA基本人口學特徵之分析..................................36
第二節 社區ORSA醫療相關暴露之分析....................................41
第三節 社區ORSA感染或移生部位之分布..................................44
第四節 社區ORSA危險因子多變項分析....................................46
第五節 社區ORSA對抗生素感受性之分析..................................47
第六節 社區ORSA菌血症之危險因子分析..................................49
第七節 社區ORSA菌血症對抗生素感受性之分析............................51

第五章 討論..........................................................52

第六章 結論..........................................................71

第七章 研究限制......................................................74

第八章 參考文獻......................................................75

表格..........................................................84
附件 105

1.吳孟儒、陳崇文 、黃嘉文等編譯。醫用微生物學，中華民國88年1月初版186-93 。
2.王聖予、李麗俐、吳秀玲等編譯，陳豪勇 鑑修，最新醫用微生物學(上冊) ，中華民國
87 年9月初版209-23。
3.李士瑋。抗生素，細菌終結者。中華民國93年1月初版 277-343。
4.Ho M, McDonald LC, Lauderdale TL, et al. Surveillance of antibiotic
resistance in Taiwan. J Microbial Immunol Infect 1999; 32:239-49.
5.Chang SC, Hsu LY, Luh KT, et al. Methicillin-resistant Staphylococcus aureus
infections. J Formos Med Associ 1988; 87:157-63.
6.Chang SC, Sun CC, Yang LS, et al. Increasing nosocomial infections of
mrthicillin-resistant Staphylococcus aureus at a teaching hospital in Taiwan.
Int J Antimicrob Agents 1997; 8 : 109-14.
7.Hsueh PR, Liu CY, Luh KT. Current status of antimicrobial resistance in
Taiwan. Emerg Infect Dis 2002; 8: 132-7.
8.Chen ML, Chang SC, Pan HJ, et al. Longistudinal analysis of Methicillin-
resistant Staphylococcus aureus isolated at a teaching hospital in Taiwan. J
Formos Med Associ 1999; 8: 426-32.
9.陳孟娟。院內抗藥性菌種感染之防護措施。感控雜誌 1999; 9: 98-107.
10.國軍退除役官兵輔導委員會台北、台中、高雄榮民總醫院，國立台灣大學醫學院附設醫
院、國立成功大學醫學院附設醫院、高雄醫學大學附設中和紀念醫院，財團法人奇美醫
院、財團法人高雄長庚醫院，三軍總醫院。中華民國89年、90年、91年、92年院內感資
料 。
11.羅文聰，王志堅，朱夢麟。社區methicillin 抗藥性金黃色葡萄球菌感染。感控雜誌
2001 ;11 :169-72.
12.CDC. Methicillin-Resistant Staphylococcus aureus skin or soft tissue
infections in a state Prison-Mississippi JAMA 2000; 287:181-2.
13.行政院衛生署疾病管制局。醫學中心加護病房院內感染季報。中華民國91年4-6月。
14.Saravolatz LD, Markowitz N, Arking L, et al. Methicillin resistant
Staphylococcus aureus : epidemiologic observations during a community-
acquired outbreak. Ann Intern Med l982; 96:11-6.
15.Fergie JE, Purcell K. Community-acquired methicillin-resistant
Staphylococcus aureus infections in south Texas children. Pediatr Infect Dis
J 2001; 20:860-83.
16.Hussain FM, Boyle-vavars, Daum RS. Community-acquired methicillin-resistant
Staphylococcus aureus colonization in healthy children attending an
outpatient pediatric clinic. Pediatr Infect Dis J 2001; 20: 763-7.
17.Voss A, Doebbeling BN. The worldwide prevalence of methicillin-resistant
Staphylococcus aureus. Int J Antimicrob Agents 1995; 5: 101-6.
18.Lee SC, Wang CH, Lee N, et al. Infection caused by methicillin-resistant
staphylococcus aureus: distinct risk factors and prognosis. J Hosp Infect
1996; 6: 131-8.
19.林永崇，葉國明，彭明業。社區感染methicillin抗藥性金黃色葡萄球菌菌血症：危險因
素、臨床表徵及結果。中華民國90年感染症醫學會第五屆第二次會員大會暨學術研討會
手冊。
20.Anonymous. From the Centers for Disease Control and Prevention: Four
pediatric deaths from community-acquired methicillin-resistant
Staphylococcus aureus –Minnesota and North Dakota, l997-1999. JAMA
1999; 282: 1123-5.
21.Herold BC, Immnergluck LC, Maranan MC, et al. Community-acquired methicillin-
resistant Staphylococcus aureus in children with no identified predisposing
risk. JAMA l998; 279: 593-8.
22.Rosario-Rosado RV, Rene AA, Jones Bobby. Descriptive analysis of patients
with community-onset and hospital-onset methicillin-resistant
staphylococcus aureus infections. Infect Control Hosp Epidemiol 2004;
25:171-3.
23.Wang JT, Lin SF, Chiu HL, et al. Molecular epidemiology and control of
nosocomial methicillin-resistant Staphylococcus aureus infection in a
teaching hospital. J Formos Med Associ 2004; 103: 32-6.
24.Lin JC, Yeh KM, Peng MY, Chang FY. Community-acquired methicillin-
resistant Staphylococcus aureus bacteremia in Taiwan : risk factors for
acquisition, clinical features and outcome. J Microbial Immunol Infect 2004;
37: 24-8.
25.Wu KC, Chiu HH, Wang JH, et al: Characteristics of community-acquired
methicillin-resistant Staphylococcus aureus in infants and children without
known risk factors. J Microbial Immunol Infect 2002; 35: 53-6.
26.Fang YH, Hsueh PR, Hu JJ, et al: Community-acquired methicillin-resistant
Staphylococcus aureus in children in nnorthern Taiwan. J Microbial Immunol
Infect 2004; 37: 29-34.
27.Chi CY, Wong WW, Fung CP, et al. Epidemiology of community-acquired
Staphylococcus aureus bacteremia. J Microbial Immunol Infect 2004; 37: 16-23.
28.Chambers HF: The changing epidemiology of staphylococcus aureus? Emerg
Infect Dis 2001; 7: 178-82.
29.Maranan MC, Moreira B, Boyle-Vavra S, et al. Antimicrobial resistance in
Staphylococci epidemiology molecular mechanism and clinical relevance.
Infect Dis clin North Am l997; 11:813-49.
30.Panlilio AL, Culver DH, Gaynes RP, et al. Methicillin-resistant
Staphylococcus aureus in US hospitals 1975-1991.Infect Control Hosp
Epidemiol 1992; 13: 582-6.
31.Boyce JM. Incidence of methicillin-resistant Staphylococcus aureus in
hospitals in the United States. Infect Control Hosp Epidemiol 1995; 16
(suppl): 19.
32.Layton MC, Hierholzer WJ, Patterson JE. The evolving epidemiology of
methicillin –resistant Staphylococcus aureus at university hospital. Infect
Control Hosp Epidemiol 1995; 16:12-7.
33.Groom AV, Wolsey DH, Naimi Ts, et al. Community-acquired methicillin-
resistant Staphylococcus aureus in a Rural American Indian Community. JAMA
2001; 286:1201-5.
34.Daum RS. Community-acquired methicillin- resistant Staphylococcus aureus
infections. Pediatr lnfect Dis J 1998; 17:745-6.
35.Scarnato F, Mallaret MR, Croize J, Kouabenan DR, et al. Incidence and
prevalence of methicillin-resistant Staphylococcus aureus nasal carriage
among healthcare workers in geriatric departments: relevance to preventive
measures. Infect Control Hosp Epidemiol 2003; 24; 456-8.
36.Cenetrs for Disease Control and Prevention. Methicillin-resistant
Staphylococcus aureus skin or soft tissue infections in a State Prison-
Mississippi, 2000. MMWR 2001; 50: 919-22.
37.Pedley TA, Hauser WA. MRSA reveal its origins. Lancet Infect Dis 2001; 1:
141-2.
38.Aia’Aldeen D. A non-multiresistant community MRSA exposes its genome.
Lacent 2002; 359: 1791-2.
39.Salim BS, Mathema B, Kreiswirth BN. Community-acquired methicillin-resistant
Staphylococcus aureus: an emerging pathogen. Infect Control Hosp Epidemiol
2003; 24; 451-5.
40.Almer LS, Shortridge VD, Nilius AM, et al. Antimicrobial susceptibility and
molecular characterization of community-acquired methicillin-resistant
Staphylococcus aureus. Diag Microbiol Infect Dis 2002; 43: 225-32.
41.Fridkin SK, Gaynes RP. Antimicrobial resistance in intensive care units.
Clin Chest Med 1999; 20: 303-16.
42.Fishbain JT, Lee JC, Nguyen HD, et al. Nosocomial Tranmission of methicillin-
resistant Staphylococcus aureus: a blinded study to establish baseline
acquisition rates. Infect Control Hosp Epidemiol 2003; 24: 415-21.
43.Baggett HC, Hennessy TW, Leman R, et al. An outbreak of community-onset
methicillin-resistant Staphylococcus aureus skin infections in southwestern
Alaska. Infect Control Hosp Epidemiol 2003; 24: 397-402.
44.Friedman ND, Kaye KS, Stout JE, et al. Health care-associated bloodstream
infections in adults: a reason to change the accepted definition of
cimmunity-acquired infections. Ann Intern Med 2002; 137: 791-7.
45.Steinberg JP, Clark CC, Hackman BO. Nosocomial and community-acquired
Staphylococcus aureus bacteremias from 1980 to 1993: impact of intravascular
devices and methicillin resistance. Clin Infect Dis 1996; 23: 255-9.
46.Loeb MB, Craven S, McGeer AJ, et al. Risk factors for resistantce to
antimicrobial agents among nursing home. Am J Epidemiol 2003; 157: 40-7.
47.Calfee DP, Durbin LJ, Germanson TP, et al. Spread of methicillin-resistant
Staphylococcus aureus (MRSA) among household contacts of individuals with
nosocomially acquired MRSA. Infect Control Hosp Epidemiol 2003; 24: 422-6.
48.張靜美，林金絲，陳依雯等。某醫學中心各加護中心院內感染金黃色葡萄球菌之調。
感控雜誌 1999; 9: 245-254。
49.林玉柔，林香蘭。某區域醫院燒傷中心Oxacillin resistant Staphylococcus aureus
群突發調查。感控雜誌 1999; 8: 687-90。
50.王麗華，楊麗瑟，潘惠如。某教學醫院燒傷加護病房methicillin抗藥性金黃色葡萄球菌
感染之調查研究。感控雜誌 1999;9: 125-33。
51. Ho PL. Carriage of methicillin-resistant Staphylococcus aureus, ceftazidime-
resistant Gram-negative bacilli, and vancomycin-resistant enterococci before
and after intensive care unit admission. Crit Care Med 2003; 31: 1175-82.
52.Blok HEM, Troelstra A, Kamp-Hopmans TEM, et al. Role of healthcare workers
in outbreaks of methicillin-resistant Staphylococcus aureus: a 10-year
evaluation from a DUTCH university hospital. Infect Control Hosp Epidemiol
2003; 24: 679-86.
53.孫春轉，楊麗瑟，潘惠如。以mupirocin 藥膏治療methicillin抗藥性金黃色葡萄球菌帶
菌者之效果評估。感控雜誌 1996;6: 125-9。
54.Anonymous. Revised guidelines for the control of methicillin-resistance
Staphylococcus aureus infection in hospitals. J Hosp Infect 1998; 39: 253-90.
55.Walker ES, Vasquez JE, Dula R, et al. Mupirocin-resistant, methicillin-
resistant Staphylococcus aureus: does mupirocin remain effect? Infect
Control Hosp Epidemiol 2003; 24: 342-6.
56.Shopsin B, Mathema B, Martinez J, et al. Prevalence of methicillin-resistant
and methicillin-susceptible Staphylococcus aureus in the community. J Infect
Dis 2000; 182:359-62.
57.Frank AL, Marcinak JF, Mangat PD, et al. Increase in community-acquired
methicillin-resistant Staphylococcus aureus in children. Clin Infect Dis
1999; 29: 935-6.
58.Naimi TS, LeDell KH, Boxrud DJ, et al. Epidemiology and clonality of
community-acquired methicillin-resistant Staphylococcus aureus in Minnesota,
1996-1998. Clid Infect Dis 2001; 33: 990-6.
59.Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community and
health care-associated methicillin-resistant Staphylococcus aureus
Infection. JAMA 2003; 290: 2976-84.
60.黃莉英，張藏能，王春玉等。某醫學中心萬古黴素使用合理性之回溯性評估。 感控雜
誌 2001; 12: 137-43。
61.Rothman KJ. Type of epidemiologic study. in Epidemioloy an introduction. 1st
Eds, New York, 2002.
62.蔡文城。實用臨床微生物診斷學，中華民國92年9月第九版 455-483,1257-88。
63.Ayliffe GAJ, Lowbury EJE. Contro of Hospital Infection, a practical
handbook. 1st Eds, London, 1992.
64.Salgado CD, Farr BM, Calfee DP. Community-acquired methicillin-resistant
Staphylococcus aureus: a meta-analysis of prevalence and risk factors. Clin
Infect Dis 2003; 36: 131-9.
65.Garner JS, Jarvis WR, Emori TG, et al. CDC definitions for nosocomial
infection, 1988. Am J Infect Control 1988; 16: 128-40.
66.Tambyah PA, Habib AG, Ng TM, et al. Community-acquired methicillin-
resistant Staphylococcus aureus infection in Singapore is usually “
healthcare associated”. Infect Control Hosp Epidemiol 2003; 24: 436-8.
67. Moreno F, Crisp C, Jorgensen JH, et al. Methicillin-resistant
Staphylococcus aureus as a community organism. Clin Infect Dis 1995; 21:
1308-12.
68.Scanvic A, Denic L, Gaillon S, et al. Duration of colonization by
methicillin-resistant Staphylococcus aureus after hospital discharge and
risk factors for prolonged carriage. Clin Infect Dis 2001; 32: 1393-8.
69. 曲佩芬，李聰明。長期照護機構之重要一環：院內感染管制。感控雜誌 2002; 12:
118-27。
70.Borer A, Gilad J, Yagupsky P, et al. Community-acquired methicillin-
resistant Staphylococcus aureus in institutionalized adults with
developmental disabilities. Emerg Infect Dis 2002; 8: 966-70.
71.D’Agelo MT, Arnold K, Parker SL, et al. Methicillin-resistant
Staphylococcus aureus infections in correctional facilities-Georgia,
California, and Texas, 2001-2003. MMWR 2003; 52: 992-4.
72.CDC. Pubic Health Dispath: Outbreak of community –associated methicillin-
resistant Staphylococcus aureus skin infections-Los Angeles county,
California, 2002-2003. http://www.cdc.org , 2004.
73.Goetz A, Posey K, Fleming J, et al. Methicillin-resistant Staphylococcus
aureus in the community: a hospital-based study. Infect Control Hosp
Epidemiol 1999; 20:689-91.
74.Warshawsky B, Hussain Z, Gregson DB, et al. Hospital-and community-based
surveillance of methicillin-resistant Staphylococcus aureus: previous
hospitalization is the major risk factor. Infect Control Hosp Epidemiol
2000;21: 724-7.
75.Jernigan JA, Pullen AL, Flowers L, et al. Prevalence of and risk factors for
conlonization with methicillin-resistant Staphylococcus aureus at the time
of hospital admission. Infect Control Hosp Epidemiol 2003; 24: 409-14.
76.Jernigan JA, Pullen AL, Flowers L, et al. Prevalence of and risk factors for
conlonization with methicillin-resistant Staphylococcus aureus in an
outpatient clinc population. Infect Control Hosp Epidemiol 2003; 24: 445-50.
77.全民健康保險局。全民健康保險和國民保健服務模式（NHS）、社會保險模型（NHI）、
美、日、韓之整體制度之比較。http://www.nhi.gov , 2004。
78.Talon D, Woronoff-Lemsi M.C., Limat S, et al. The impact of resistance to
methicillin in Staphylococcus aureus bacteremia on mortality. Eur J Infect
Med 2001; 13: 31-6.
79.Johnson LB, Bhan A, Pawlak J, et al. Changing epidemiology of community-
onset methicillin-resistant Staphylococcus aureus bacteremia. Infect Control
Hosp Epidemiol 2003; 24: 431-5.
80.Topeli A, Unal S, Akalin HE. Risk factors influencing clinical outcome in
Staphylococcus aureus bacteremia in a Turkish university hospital. Int J
Antimicrol Agents 2000; 14: 57-63.